Trevi Therapeutics (NASDAQ:TRVI) management used the company’s first-quarter 2026 earnings call to outline upcoming clinical milestones for its chronic cough programs and to highlight an expanded cash runway following an April equity offering. Clinical program updates and upcoming trial starts President and CEO Jennifer Good said 2026 is “an important year of execution,” and noted […]

Nuvation Bio (NYSE:NUVB) executives said the company made continued commercial progress with ROS1-positive non-small cell lung cancer (NSCLC) therapy Ibtrozi during the first quarter of 2026, pointing to steady new patient demand, a shifting mix toward first-line use, and rising product revenue as more patients remain on treatment longer. Commercial launch trends for Ibtrozi Founder, […]